Drug Database
L01 ANTINEOPLASTIC AGENTS
Approved by UK Medicines & Healthcare Products Regulatory Agency & the European Medicines Agency.
- L01AA01 cyclophosphamide
- L01AA02 chlorambucil
- L01AA03 melphalan
- L01AA05 chlormethine
- L01AA06 ifosfamide
- L01AA09 bendamustine
- L01AB01 busulfan
- L01AB02 treosulfan
- L01AC01 thiotepa
- L01AD01 carmustine
- L01AD02 lomustine
- L01AD04 streptozocin
- L01AX03 temozolomide
- L01AX04 dacarbazine
- L01BA01 methotrexate
- L01BA03 raltitrexed
- L01BA04 pemetrexed
- L01BB02 mercaptopurine
- L01BB03 tioguanine
- L01BB04 cladribine
- L01BB05 fludarabine
- L01BB06 clofarabine
- L01BB07 nelarabine
- L01BC01 cytarabine
- L01BC02 fluorouracil
- L01BC05 gemcitabine
- L01BC06 capecitabine
- L01BC07 azacitidine
- L01BC08 decitabine
- L01BC52 fluorouracil, combinations
- L01BC53 tegafur, combinations
- L01BC58 decitabine, combinations
- L01BC59 trifluridine, combinations
- L01CA01 vinblastine
- L01CA02 vincristine
- L01CA03 vindesine
- L01CA04 vinorelbine
- L01CA05 vinflunine
- L01CB01 etoposide
- L01CD01 paclitaxel
- L01CD02 docetaxel
- L01CD04 cabazitaxel
- L01CE01 topotecan
- L01CE02 irinotecan
- L01CX01 trabectedin
- L01DA01 dactinomycin
- L01DB01 doxorubicin
- L01DB02 daunorubicin
- L01DB03 epirubicin
- L01DB06 idarubicin
- L01DB07 mitoxantrone
- L01DB11 pixantrone
- L01DC01 bleomycin
- L01DC03 mitomycin
- L01EA01 imatinib
- L01EA02 dasatinib
- L01EA03 nilotinib
- L01EA04 bosutinib
- L01EA05 ponatinib
- L01EA06 asciminib
- L01EB01 gefitinib
- L01EB02 erlotinib
- L01EB03 afatinib
- L01EB04 osimertinib
- L01EB07 dacomitinib
- L01EB10 mobocertinib
- L01EC01 vemurafenib
- L01EC02 dabrafenib
- L01EC03 encorafenib
- L01ED01 crizotinib
- L01ED02 ceritinib
- L01ED03 alectinib
- L01ED04 brigatinib
- L01ED05 lorlatinib
- L01EE01 trametinib
- L01EE02 cobimetinib
- L01EE03 binimetinib
- L01EE04 selumetinib
- L01EF01 palbociclib
- L01EF02 ribociclib
- L01EF03 abemaciclib
- L01EG01 temsirolimus
- L01EG02 everolimus
- L01EH01 lapatinib
- L01EH02 neratinib
- L01EH03 tucatinib
- L01EJ01 ruxolitinib
- L01EJ02 fedratinib
- L01EJ04 momelotinib
- L01EK01 axitinib
- L01EK03 tivozanib
- L01EL01 ibrutinib
- L01EL02 acalabrutinib
- L01EL03 zanubrutinib
- L01EM01 idelalisib
- L01EM03 alpelisib
- L01EN02 pemigatinib
- L01EX01 sunitinib
- L01EX02 sorafenib
- L01EX03 pazopanib
- L01EX04 vandetanib
- L01EX05 regorafenib
- L01EX07 cabozantinib
- L01EX08 lenvatinib
- L01EX09 nintedanib
- L01EX10 midostaurin
- L01EX12 larotrectinib
- L01EX13 gilteritinib
- L01EX14 entrectinib
- L01EX18 avapritinib
- L01EX19 ripretinib
- L01EX21 tepotinib
- L01EX22 selpercatinib
- L01EX23 pralsetinib
- L01FA01 rituximab
- L01FA03 obinutuzumab
- L01FB01 inotuzumab ozogamicin
- L01FC01 daratumumab
- L01FC02 Isatuximab
- L01FD01 trastuzumab
- L01FD02 pertuzumab
- L01FD03 trastuzumab emtansine
- L01FD04 trastuzumab deruxtecan
- L01FE01 cetuximab
- L01FE02 panitumumab
- L01FF01 nivolumab
- L01FF02 pembrolizumab
- L01FF03 durvalumab
- L01FF04 avelumab
- L01FF05 atezolizumab
- L01FF06 cemiplimab
- L01FF07 dostarlimab
- L01FG01 bevacizumab
- L01FG02 ramucirumab
- L01FX02 gemtuzumab ozogamicin
- L01FX04 ipilimumab
- L01FX05 brentuximab vedotin
- L01FX06 dinutuximab beta
- L01FX07 blinatumomab
- L01FX08 elotuzumab
- L01FX09 mogamulizumab
- L01FX12 tafasitamab
- L01FX13 enfortumab vedotin
- L01FX14 polatuzumab vedotin
- L01FX15 belantamab mafodotin
- L01FX17 sacituzumab govitecan
- L01FX18 amivantamab
- L01FX20 tremelimumab
- L01FX22 loncastuximab tesirine
- L01FX24 teclistamab
- L01FX25 mosunetuzumab
- L01FX27 epcoritamab
- L01FX28 glofitamab
- L01FX29 talquetamab
- L01FX32 elranatamab
- L01XA01 cisplatin
- L01XA02 carboplatin
- L01XA03 oxaliplatin
- L01XB01 procarbazine
- L01XD03 methyl aminolevulinate
- L01XD04 aminolevulinic acid
- L01XD07 padeliporfin
- L01XF01 tretinoin
- L01XF03 bexarotene
- L01XG01 bortezomib
- L01XG02 carfilzomib
- L01XG03 ixazomib
- L01XH03 panobinostat
- L01XJ01 vismodegib
- L01XJ03 glasdegib
- L01XK01 olaparib
- L01XK02 niraparib
- L01XK03 rucaparib
- L01XK04 talazoparib
- L01XL02 Talimogene laherparepvec
- L01XL03 Axicabtagene ciloleucel
- L01XL04 Tisagenlecleucel
- L01XL06 Brexucabtagene autoleucel
- L01XX01 amsacrine
- L01XX02 asparaginase
- L01XX05 hydroxycarbamide
- L01XX08 pentostatin
- L01XX23 mitotane
- L01XX24 pegaspargase
- L01XX27 arsenic trioxide
- L01XX35 anagrelide
- L01XX41 eribulin
- L01XX44 aflibercept
- L01XX52 venetoclax
- L01XX62 ivosidenib
- L01XX73 sotorasib
- L01XX74 belzutifan
- L01XX75 tebentafusp
- L01XY01 cytarabine and daunorubicin
Learning Zones
Disclaimer
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drug Licencing
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).